EcoDrugPlus

Bruton Tyrosine Kinase

Ensembl ID : ENSKMAG00000019808
Gene Symbol: BTK
3 Cross references
204 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSKMAG00000019285
Gene Symbol: LOC108251323
3 Cross references
188 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSKMAG00000017561
Gene Symbol: CCR9
3 Cross references
193 Possible Orthologues:

C-X-C Motif Chemokine Receptor 1

Ensembl ID : ENSKMAG00000019057
Gene Symbol: CXCR1
1 Cross references
275 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSKMAG00000015064
Gene Symbol: CXCR4
4 Cross references
201 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSKMAG00000005859
Gene Symbol: LOC108241058
2 Cross references
406 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSKMAG00000004497
Gene Symbol: CFTR
3 Cross references
214 Possible Orthologues:

D(1)-Like Dopamine Receptor

Ensembl ID : ENSKMAG00000009582
Gene Symbol: LOC108238994
3 Cross references
199 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSKMAG00000016648
Gene Symbol: DNMT1
2 Cross references
210 Possible Orthologues:

Dna Topoisomerase 2-Beta-Like

Ensembl ID : ENSKMAG00000014294
Gene Symbol: LOC108229151
2 Cross references
207 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSKMAG00000021133
Gene Symbol: TOP1
3 Cross references
207 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSKMAG00000018356
Gene Symbol: TOP1
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).